Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
In development
Reference number: GID-TA11220
Expected publication date: TBC
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of lecanemab for treating early Alzheimer's disease.
Please note that at the request of the company, the timelines for this appraisal have been revised to allow them to develop a robust and comprehensive submission; the appraisal is now anticipated to begin in late August 2023.